Abbvie (ABBV) says that Apogee's global Phase 3 atopic dermatitis program is seen to begin enrollment in 2026, targeting an early-2030 launch

When an established player volunteers a read on a rival's enrollment timeline and launch window, the subtext is usually competitive positioning: affirming that the threat is distant and that its own franchise has runway. The mechanism that matters for the peer set is duration of exclusivity in the class, since a later entrant launch extends the incumbent's pricing and share protection, while any acceleration compresses it. The distinction worth drawing is between the incumbent's own commentary, which is promotional by nature, and the challenger company's disclosed trial milestones, which are the verifiable tells. Historically, Phase 3 timelines in dermatology have slipped more often than they have accelerated, and early-2030s launch targets carry wide error bars around enrollment pace and regulatory review. What is worth watching next is the challenger's own enrollment disclosures and any read-through from interim data, rather than the incumbent's framing of them.